A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
← catalyst calendarNCT07277231 · readout ≤ 1,654 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
500estimated
Sites
105
Countries
Australia, Brazil, Canada +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-22 | actual | When the study began enrolling |
| Primary completion | Feb 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Lymphocytic Leukemia
Interventions
- Drug: Sonrotoclax — also filed as BGB-11417
- Drug: Zanubrutinib — also filed as BGB-3111, Brukinsa
- Drug: Acalabrutinib — also filed as Calquence
- Drug: Venetoclax — also filed as Venclexta, Venclyxto
Primary outcomes
what the primary-completion date above is the date OFProgression-Free Survival (PFS) as Determined by Independent Review Committee (IRC)
measured Up to approximately 70 months
Rate of Undetectable Minimal Residual Disease at < 10^-4 sensitivity (uMRD4)
measured Up to approximately 16 months
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed